The combination of mIgG2a anti-TIGIT and anti-PD-L1 antibodies did not control tumour growth in FcγR-knockout mice, confirming a requirement for Fc–FcγR engagement for therapeutic activity of anti-TIGIT monoclonal antibodies in this model (Extended Data Fig. 4b). This evidence concerns the gene TIGIT and neoplasm.